Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
- 30 September 2010
- journal article
- review article
- Published by Elsevier BV in Schizophrenia Research
- Vol. 122 (1-3), 1-23
- https://doi.org/10.1016/j.schres.2010.05.025
Abstract
No abstract availableKeywords
This publication has 123 references indexed in Scilit:
- HTS and Rational Drug Design to Generate a Class of 5‐HT2C‐Selective Ligands for Possible Use in Schizophrenia.ChemMedChem, 2010
- The Promise and Reality of Pharmacogenetics in PsychiatryPsychiatric Clinics of North America, 2010
- GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disordersNeuropharmacology, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophreniaDrug Discovery Today, 2009
- Influence of antipsychotics on mortality in schizophrenia: Systematic reviewSchizophrenia Research, 2009
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2009
- Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophreniaSchizophrenia Research, 2009
- A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?Archives of General Psychiatry, 2007
- Schizophrenia and employmentSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004